E6(R3) is the latest revision of the international Good Clinical Practice guideline. Its biggest change is in mindset: quality should be designed into a trial from the start, not inspected in at the end.
Quality by design
Sponsors are expected to identify the factors that matter most to participant safety and reliable results, then focus monitoring and controls on those.
Proportionate, risk-based approach
Not every data point needs the same level of checking. The guideline supports targeted and centralised monitoring where it makes sense.
Room for modern trial designs
The text is written to accommodate decentralised elements, digital tools and real-world data sources.
What to do now
Review your SOPs and monitoring plans against the new principles, and make sure your team understands why each control exists, not just what it is.